Integrase Inhibitors Market, By Drug (Raltegravir, Dolutegravir, Elvitegravir, Bictegravir, and Others (Cabotegravir, etc.)), By Route of Administration (Oral, Intravenous, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Oct 2023

Code : CMI6023

Pages :150

Formats :

Excel and PDF

Industry : Pharmaceutical

Integrase Inhibitors MarketSize and Trends

The global integrase inhibitors market size was valued at US$ 14.7 billion in 2023 and is expected US$ 21.7 billion by 2030 is expected to grow at a compound annual growth rate (CAGR) of 5.7% from 2023 to 2030. The increasing adoption of integrase inhibitors as first-line therapy for HIV, the rising prevalence of HIV/AIDS, and the growing government initiatives to improve HIV treatment and prevention programs are the major factors driving the growth of the market.

Integrase Inhibitors Market Trends

New Product Launches: Pharmaceutical companies continue to introduce new integrase inhibitors with improved properties, such as enhanced efficacy, safety, and resistance profiles. These innovations contribute to the expansion of the market and provide healthcare providers with a wider range of treatment options. For instance, in June 2020, ViiV Healthcare group, a multinational pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved Tivicay PD (dolutegravir) tablets for oral suspension, which are used in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in pediatric patients
Resistance Monitoring and Management: The emergence of drug-resistant strains of HIV poses a challenge in HIV/AIDS treatment. As a result, there is a growing emphasis on resistance monitoring and management strategies, including the use of integrase resistance testing. This trend drives the development of new integrase inhibitors that are effective against resistant strains and the incorporation of resistance testing into treatment guidelines.

Recent Developments

New product approvals

On September 5 2023, Viatris Inc., a global healthcare company, announced the U.S. Food and Drug Administration (FDA) tentative approval for a New Drug Application for abacavir 60 mg/dolutegravir 5 mg/lamivudine 30 mg tablets for oral suspension for the treatment of HIV-1 infection in pediatric patients.
In March 2022, Johnson & Johnson Services, Inc., a multinational, pharmaceutical and medical technologies corporation, announced the U.S. Food and Drug Administration (FDA) had approved CABENUVA (cabotegravir and rilpivirine) for the treatment of HIV-1 in virologically suppressed adolescents.
In February 2022, ViiV Healthcare group, a multinational pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved Cabenuva (cabotegravir, rilpivirine) for every-two-month dosing for the treatment of HIV-1 in virologically suppressed adults